Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Download

Total Articles

15
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (7)

Searched Name

E Felip Font

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

First Author Affiliations

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Corresponding Author Affiliations

Show more Refine

Category

Show more Refine

Number

Citation Analysis

Ponce Aix S, Carcereny Costa E, Bosch-Barrera J, Felip Font E, Guirado M, Coves Sarto J, Majem Tarruella M, Juan Vidal O, Dalmau Portulas E, Diz P, Ortega Granados A, Domine Gomez M, Blasco Cordellat A, Mosquera Martinez J, Sala Gonzalez M, Dorta M, Calvo de Juan V, Zugazagoitia J, Enguita A, Paz-Ares L. 160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open

Andric Z, Gálffy G, Dols MC, Szima B, Stojanovic G, Petrovic M, Font EF, Baz DV, Aix SP, Juan-Vidal O, Tehenes S, Szalai Z, Losonczy G, Blanco AC, Bernabe R, Duecker K, Zhou D, Schroeder A, Guezel G, Ciardiello F. 103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC). J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01945-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]

Camidge D, Janku F, Bueno AM, Catenacci D, Lee J, Lee SH, Chung H, Dowlati A, Rohrberg K, Felip Font E, Garralda E, Kang YK, Moon Y, López Criado M, Chiu CF, Poulsen T, Rudbæk H, Alifrangis L, Dalal R, Patnaik A. A phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open

Matos Garcia I, García Ruiz A, Martin-Liberal J, Hierro C, Ochoa De Olza Amat M, Viaplana C, Mur G, Vieito Villar M, Brana I, Azaro A, Perez C, Rodriguez Freixinos V, Argiles G, Oliveira M, Felip Font E, Muñoz-Couselo E, Tabernero J, Dienstmann R, Garralda E. Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open

Cedres Perez S, Sanso M, Hernando-Calvo A, Callejo A, Pardo Aranda N, Navarro Mendivil A, Martinez A, Remon J, Miquel J, Rodriguez G, Monton V, Villacampa G, Dienstmann R, Vivancos A, Felip Font E. Multiple primary cancers (MPC) in a series of lung cancer (LC) patient: Incidence and outcome. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open

Karachaliou N, Lefterova M, Draper J, Molina MA, Chaib I, Palmero R, Taus A, Viteri S, González Cao M, Majem Tarruella M, Carcereny Costa E, Moran T, Garde Noguera J, Felip Font E, Olsen S, Jackson M, Sampayo M, Faull I, Dix D, Rosell R. Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy304.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open

Palmero R, Taus Á, Majem Tarruella M, Viteri S, Carcereny Costa E, Garde J, Felip Font E, Cassidy C, Dix D, Karachaliou N, Rosell R. Prospective comparison of liquid biopsy to standard of care tissue testing in metastatic, non-squamous, non-small cell lung cancer (NSCLC) patients (pts). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open

Besse B, Shaw A, Solomon B, Bauer T, Chiari R, Lin CC, Satouchi M, Clancy J, James L, Abbattista A, Felip Font E. Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open

Remon J, Martinez-Marti A, Carcereny Costa E, Zeron-Medina Cuairan J, Sansano I, Mate J, Pardo N, Cedres S, Navarro A, Martinez de castro A, Moran T, Felip Font E. Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx381.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open

Popat S, Ardizzoni A, Ciuleanu T, Cobo Dols M, Laktionov K, Szilasi M, Califano R, Carcereny Costa E, Griffiths R, Paz-Ares L, Szczylik C, Corral J, Isla D, Jassem J, Appel W, Van Meerbeeck J, Wolf J, Jiang J, Molife L, Felip Font E. Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open

Felip Font E, Shaw A, Solomon B, Bauer T, Ou SH, Gadgeel S, Soo R, Seto T, Clancy J, James L, Abbattista A, Besse B. Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) previously treated with 2nd-generation ALK TKIs. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open

Cedres S, Martinez Marti A, Navarro A, Pardo N, Remon J, Matos I, Ochoa de Olza M, Hierro C, Martin Liberal J, Miquel J, Viaplana C, Villacampa Javierre G, Dienstmann R, Felip Font E. Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated with immune-oncology drugs (IO) in clinical trials. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx389.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open

Felip Font E, Gettinger S, Burgio M, Antonia S, Holgado E, Spigel D, Arrieta O, Domine Gomez M, Aren Frontera O, Brahmer J, Chow L, Crinò L, Butts C, Coudert B, Horn L, Steins M, Geese W, Li A, Healey D, Vokes E. Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open

Eberhardt W, Garassino MC, Rizvi NA, Besse B, Jänne PA, Peters S, Keong Toh C, Kurata T, Carcereny Costa E, Koczywas M, Felip Font E, Chaft J, Qiu J, Kowanetz M, Zou W, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson ML. Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study. Pneumologie 2017. [DOI: 10.1055/s-0037-1598277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]

Felip Font E, Hernández Hernández JA, Pigrau Serrallach C, Martínez Vázquez JM. [Pleural effusion as a form of presentation of Waldenström's macroglobulinemia]. An Med Interna 1989;6:390-1. [PMID: 2518825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]